Aggrecanase-1 is one of two novel cartilage-degrading metalloproteases purified from bovine nasal cartilage cultures stimulated with interleukin-1 (1, 2). The enzyme shares 40 -50% sequence homology with aggrecanase-2 (ADAMTS-11/5), ADAMTS-1 (METH-1), and ADAMTS-8 (METH-8) as well as lower degrees of homology with other members of the a disintegrin and metalloprotease with thrombospondin motif (AD-AMTS) 1 family (3-7). All members of the ADAMTS family consist of an N-terminal propeptide domain, a metalloproteinase domain, and a disintegrin-like domain, resembling the structural elements of the reprolysin family of metalloproteases that includes the a disintegrin and metalloprotease (ADAM) and snake venom metalloproteases (8, 9). Unlike typical ADAM proteins that are membrane-anchored and have a transmembrane domain and cytoplasmic domain in the C-terminal region, the C terminus of ADAMTS proteins contains a varying number of thrombospondin type-1 (TSP-1) motifs, the sequence of which is the conserved motif in thrombospondin 1 and 2 (10).
50% sequence homology with aggrecanase-2 (ADAMTS-11/5), ADAMTS-1 (METH-1), and ADAMTS-8 (METH-8) as well as lower degrees of homology with other members of the a disintegrin and metalloprotease with thrombospondin motif (AD-AMTS) 1 family (3) (4) (5) (6) (7) . All members of the ADAMTS family consist of an N-terminal propeptide domain, a metalloproteinase domain, and a disintegrin-like domain, resembling the structural elements of the reprolysin family of metalloproteases that includes the a disintegrin and metalloprotease (ADAM) and snake venom metalloproteases (8, 9) . Unlike typical ADAM proteins that are membrane-anchored and have a transmembrane domain and cytoplasmic domain in the C-terminal region, the C terminus of ADAMTS proteins contains a varying number of thrombospondin type-1 (TSP-1) motifs, the sequence of which is the conserved motif in thrombospondin 1 and 2 (10) .
Aggrecan is a large chondroitin sulfate proteoglycan that accounts for about 10% of the dry weight of cartilage (11, 12) . It consists of three globular domains: G1, through which it interacts with hyaluronan (HA); G2; and G3 at the C terminus of the molecule. The core protein between G2 and G3 is highly substituted with the glycosaminoglycans (GAG) keratin sulfate and chondroitin sulfate chains. Aggrecan is usually found as part of a large aggregate with HA containing approximately 100 proteoglycan molecules/HA molecule. The molecule carries a large number of fixed negatively charged groups on the GAGs that results in high osmotic pressure in the tissue, thus allowing aggrecan to swell and hydrate the framework of collagen fibrils in cartilage, providing the tissue its properties of compressibility and resilience.
The interglobular domain of aggrecan between the G1 and G2 domain has been shown to be susceptible to proteolytic cleavage. In fact, aggrecanase activity was originally defined by cleavage at the Glu 373 /Ala 374 bond within this region of the aggrecan core protein (13) . We have recently demonstrated that recombinant aggrecanase-1 degrades cartilage aggrecan very efficiently and cleaves sequentially at five sites within the molecule (14) . 2 Several cleavages occur first in the chondroitinsulfate-rich region of the molecule followed by cleavage within the interglobular domain between residues Glu 373 and Ala
374
. Fragments formed by aggrecanase-mediated cleavage are found in cartilage cultures stimulated with cytokines or retinoic acid (13, (15) (16) (17) (18) (19) (20) (21) (22) (23) , 3 as well as in synovial fluid from patients * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
with rheumatoid and osteoarthritis (24, 25) , suggesting that aggrecanase-1 and aggrecanase-2 may be important in the destruction of cartilage aggrecan in arthritic diseases.
Aggrecanase-1, like all of the ADAMTS proteins, contains a TSP-1 motif with sequences similar to segments in thrombospondin 1 and 2 that have been implicated in binding (Fig. 1) . The sequence W(S/G)XW has been implicated in the interaction of thrombospondin with the sulfated GAG chains of heparin, heparin sulfate, and chondroitin sulfate (26, 27) , and the sequence CSVTCG has been shown to bind to the thrombospondin receptor, CD36 (28) . In addition, it has been reported that the TSP-1 motifs of murine ADAMTS-1 bind to heparin and the extracellular matrix (9, 29) . This opens the possibility that this region in aggrecanase-1 may serve to bind the enzyme to the glycosaminoglycans of the aggrecan molecule. We recently demonstrated that deglycosylation of aggrecan decreases the ability of aggrecanase activity in culture media to generate aggrecan fragments formed by cleavage at the Glu 373 /Ala 374 bond (30), 3 which is consistent with this hypothesis. Therefore, the goal of the studies reported herein was to determine whether aggrecanase-1 recognizes aggrecan through binding of the TSP-1 motif to the aggrecan glycosaminoglycans, chondroitin sulfate and keratan sulfate, and whether binding of the enzyme to these glycosaminoglycans is important for cleavage of the core protein. , and lacking the disintegrin and TSP motif, were expressed in Drosophila cells as described previously (1) . Both the fulllength and truncated forms of aggrecanase-1 were purified from the fermentation medium as follows. Media were loaded onto a Macro S column (Bio-Rad) and aggrecanase-1 protein eluted with a linear gradient of 0.1-1 M NaCl in 50 mM Hepes buffer containing 10 mM CaCl 2 , 0.1 M NaCl at pH 7.5. The majority of the aggrecanase-1 eluted with 0.6 -0.7 M NaCl. These fractions were pooled and concentrated using an Amicon Diaflo pressure concentrator fitted with a YM-30 membrane, and then loaded onto a Superdex 200 HR10/30 gel filtration column (Amersham Pharmacia Biotech). The protein was eluted isocratically at 1 ml/min, and pooled fractions containing the aggrecanase-1 were concentrated for further evaluation. Proteolytic activity of truncated aggrecanase-1 was confirmed by demonstrating that it binds to ␣ 2 -macroglobulin as evaluated by the inability of the bound material to enter an SDS-polyacrylamide gel. Since the binding of a proteinase and ␣ 2 -macroglobulin is initiated by proteolysis of the "bait" region of the ␣ 2 -macroglobulin, which in turn triggers large conformational changes and entraps the proteinase (31) , binding confirms the activity of the aggrecanase-1. In addition, both the full-length and truncated aggrecanase-1 cleaved a peptide substrate containing the aggrecanase-sensitive cleavage site, NITEGE-ARGS. 4 ADAMTS-1 Expression-Full-length ADAMTS-1 was expressed in the same Drosophila system as aggrecanase-1. The activity of the protein was confirmed by showing it binds to ␣ 2 -macroglobulin.
MATERIALS AND METHODS

Aggrecanase
Thrombospondin Peptides-Overlapping peptides to the TSP motif were synthesized at Quality Controlled Biochemicals, Inc. (Hopkinton, MA). These peptides included GGWGPWGPWGD, GGWGPWGPWG-DCSRTCGGG, SRTCGGGVQFSSRDCTRPV, SSRDCTRPVPRNG-GKYCEGRR, and GGKYCEGRRTRFRSCNTEDCP.
Antibodies-The monoclonal antibody, MAB2035, which recognizes chondroitin sulfate stubs on the core protein of aggrecan following deglycosylation, was purchased from Chemicon International (Temecula, CA). Neoepitope antibodies were used to detect fragments generated by aggrecanase-mediated cleavage at sites shown in Fig. 2 Specificity of these antibodies was determined in competitive ELISA using synthetic peptide antigens as inhibitors. Intact, undigested aggrecan was not detected with any of the antibodies, and competition experiments confirmed that peptides spanning the cleavage sites did not block antibody binding to aggrecanase-1-digested aggrecan fragments, while peptides containing the external neoepitope sequences did block binding of the antibodies to aggrecan fragments.
Bovine Aggrecan Isolation-Nasal septa were removed from bovine noses obtained fresh from slaughter. The cartilage was sliced, and aggrecan was extracted by stirring at 4°C for 48 h in 10 volumes of 4 M guanidine-HCl in 0.05 M sodium acetate, pH 5.8, containing the protease inhibitors, 0.01 M EDTA, 0.1 M 6-aminohexanoic acid, 2 mM phenymethanesulfonyl fluoride, and 0.05 M benzamidine HCl. Aggrecan monomers were isolated by equilibrium density gradient centrifugation in cesium chloride (33) , and the bottom of this gradient (d Ͼ 1.54 g/ml) containing the monomers was dialyzed at 4°C against water, lyophilized, and stored at Ϫ20°C.
Generation of GAG-free Aggrecan-Chondroitin sulfate and keratan sulfate glycosaminoglycans were removed from bovine aggrecan monomers using chondroitinase ABC, keratanase, and keratanase II (Seikagaku, Cape Cod, MA). 0.1 units of chondroitinase ABC, keratanase, and 0.01 units of keratanase II per 10 g of aggrecan was allowed to incubate for 4 h at 37°C in 100 mM Tris/HCl with 100 mM sodium acetate, pH 6.5.
Enzyme Digestion-Digestions were carried out in 100 l of 50 mM Tris/HCl buffer, pH 7.5, containing 100 mM NaCl and 10 mM CaCl 2 . Purified bovine aggrecan (500 nM) was incubated with recombinant human aggrecanase-1 (full-length or truncated) at 37°C for the indicated times. To evaluate the ability of TSP peptides to block aggrecanase activity, the peptides at concentrations from 0.1 to 100 M were incubated with 500 nM bovine aggrecan for 30 min at room temperature. Aggrecanase-1 was then added, and the reaction mixtures incubated for 5 h. The reactions were quenched with EDTA and analyzed by immunolocation with neoepitope antibodies.
Western Blot Analysis-For analysis of fragments by Western blot, aggrecan was enzymatically deglycosylated with chondroitinase ABC (0.1 units/10 g of aggrecan) for 1 h at 37°C and then with keratanase rated proteins were transferred to polyvinylidene difluoride membranes and immunolocated with a 1:1000 dilution of one of the above neoepitope antibodies. Subsequently, the membranes were incubated with a 1:5000 dilution of goat anti-mouse or goat anti-rabbit IgG alkaline phosphatase conjugate for the neo-epitope antibodies. Neoepitope-reactive aggrecan cleavage products were visualized by developing the blots in nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate color developing reagent. Overnight transfer resulted in complete transfer of both low and high molecular fragments, and the densitometric response was found to be linear over the density ranges required for the blots. The neoepitope-reactive fragments were quantified by scanning densitometry.
Binding Assay-500 nM aggrecan or GAG-free aggrecan was incubated with 1 nM recombinant aggrecanase-1, in the presence or absence of 100 M TSP peptide, GGWGPWGPWGDCSRTCGGG, in Tris buffer for 30 min. Free aggrecanase-1 was separated from bound enzyme by passing the solution through 500-or 100-kDa size exclusion membrane filter units (Microcon-100, Millipore Corp., Beverly, MA). The filtrates were analyzed for unbound enzyme in an aggrecanase-1 ELISA. The K d of aggrecanase-1binding was estimated by incubating aggrecanase-1 (1 nM) for 30 min with aggrecan monomer (0.1-500 nM) and plotting percentage of bound aggrecanase-1 against aggrecan concentration. The IC 50 for inhibition by the TSP peptide was estimated by incubating aggrecanase-1 (1 nM) for 15 min with the peptide (0.1-100 M), followed by incubation with the aggrecan monomer (500 nM) for 30 min at 37°C and plotting percentage of bound aggrecan versus the concentration of peptide. The K i for the TSP peptide was calculated from the IC 50 using the following equation.
Aggrecanase-1 ELISA-A rabbit polyclonal antibody to the sequence VMAHVDPEEP within the catalytic domain of aggrecanase-1 was generated (1). The antibody recognizes both denatured and native enzyme and is used in a direct ELISA. The samples containing aggrecanase-1 were coated on a polyvinylidene difluoride membrane plate (Millipore, Beverly, MA) and were incubated overnight. The plates were then blocked with 5% bovine serum albumin in Tris-buffered saline. The aggrecanase-1 antibody was then added at a 1:1000 dilution and incubated for 1 h. The plates were washed three times using Tris-buffered saline and the secondary antibody, goat anti-rabbit alkaline phosphatase (Promega, Madison, WI), was added at a 1:5000 dilution and incubated for 1 h. The plates were washed three times, developed using p-nitrophenyl phosphate substrate (KPL, Gaithersburg, MD), and read at 405 nm using a spectrophotometer. Purified recombinant full-length active aggrecanase-1 was used to characterize the aggrecanase-1 ELISA, with linearity being maintained over 2 logs in a standard curve with aggrecanase-1 ( Table I ). The polyclonal antiserum was specific for aggrecanase-1 and did not recognize aggrecanase-2 or ADAMTS-1 (data not shown).
RESULTS
Active recombinant human full-length aggrecanase-1 (Phe 213 -Lys 837 ) was compared with active recombinant truncated (Phe 213 -Pro 431 ) aggrecanase-1 for the ability to cleave bovine aggrecan at the Glu 373 /Ala 374 site. The concentration of the full-length and truncated enzymes was determined by active site titration (34) against a peptide substrate containing the TEGE-ARGS aggrecanase cleavage site using a tight-binding hydroxamate inhibitor, and equal amounts of the fulllength and truncated form were incubated with native aggrecan for 5 h at 37°C. Following the incubation, aggrecan cleavage products were detected by Western blot analysis using the MAB2035 antibody. The full-length form of the enzyme cleaved aggrecan resulting in disappearance of the intact aggrecan and the generation of lower molecular mass fragments (Fig. 3) . In contrast, the truncated form of the enzyme, which lacks the TSP-1 motif and disintegrin-like domain, did not result in a decrease in intact aggrecan or the generation of any detectable fragments. These data suggested that the C terminus of the aggrecanase-1 is important for cleavage of aggrecan.
To examine whether the loss of activity by truncation was related to the removal of the TSP-1 motif from aggrecanase-1, overlapping peptides corresponding to various regions of the TSP-1 motif were tested for their ability to block cleavage of bovine aggrecan at the Glu 373 /Ala 374 site (Fig. 4) . Full-length aggrecanase-1 was incubated with aggrecan in the presence or absence of the TSP-1 peptides, and cleavage of aggrecan at the Glu 373 /Ala 374 site was monitored by Western analysis using the BC-3 antibody. Peptide 1, GGWGPWGPWGD, representing the N-terminal region of the TSP-1 motif containing the putative GAG binding motif, inhibited cleavage of aggrecan, with an IC 50 value of 17 M. Peptide 2, GGWGPWGPWGDCS-RTCGGG, containing both the GAG and CD36 binding motifs was the most potent in blocking cleavage of aggrecan, with an IC 50 of 3 M. Peptides 3 and 4, representing the middle sequences of the TSP motif, were relatively ineffective in blocking aggrecan cleavage with IC 50 values of 70 and Ͼ100 M, respectively. Finally, peptide 5, containing the C-terminal sequence of the TSP-1 motif, showed modest inhibition of aggrecan cleavage, with an IC 50 of 38 M.
Peptide 2, which exhibited the greatest potency in blocking cleavage of aggrecan between residues Glu 373 and Ala 374 , was then evaluated for the ability to block aggrecanase cleavage at the preferential sites within the C terminus of the molecule between residues Glu 1667 and Gly 1668 and between Glu 1480 and Gly 1481 (35) . Aggrecanase-1 was incubated with aggrecan in the presence or absence of 100 M peptide, and the reaction mixture was analyzed for aggrecan fragments generated by cleavage between residues Glu 1667 /Gly 1668 , residues Glu 1480 / Gly 1481 , and residues Glu 373 /Ala 374 using the anti-KEEE, anti-GELE, and anti-ARGS (BC-3) antibodies, respectively. Western blot analysis showed that this peptide blocked cleavage of aggrecan almost completely at all three sites (Fig. 5) .
FIG. 2. Sites of cleavage of aggrecan by aggrecanase-1 (AD-AMTS-4).
Aggrecanase-1 cleaves native aggrecan first within the chondroitin sulfate-rich region between the G2 and G3 domains to generate G1 fragments with the new C terminus: KEEE (1) and GELE (2), respectively. This is followed by cleavage within the interglobular domain between the G1 and G2 domains to generate a C-terminal fragment with the new N terminus: ARGS (3). Neoepitope antibodies raised against these peptide sequences were used to detect aggrecan fragments generated by cleavage at these sites. This peptide was also tested for the ability to prevent aggrecanase-1 from binding to aggrecan. Aggrecanase-1 was incubated with native aggrecan or GAG-free aggrecan in the presence or absence of 100 M TSP peptide 2. The free aggrecanase-1 was separated from bound enzyme by passing the reaction mixture through a 100-kDa size exclusion membrane filter. Native aggrecan and GAG-free aggrecan, both of which have a molecular mass of Ͼ350 kDa, are retained. In contrast, free aggrecanase-1 with a molecular mass of ϳ62 kDa readily passes through the membrane, while aggrecanase-1 bound to aggrecan is retained. In order to determine the percentage of aggrecanase-1 bound, the filtrate was analyzed for aggrecanase-1 by ELISA. Aggrecanase-1 that incubated with native aggrecan was completely bound (Table II) . In contrast, aggrecanase-1 that incubated with GAG-free aggrecan was Ͻ10% bound, and aggrecanase-1 that incubated with native aggrecan in the presence of TSP peptide was entirely unbound.
The K d for aggrecanase-1 binding to aggrecan was next determined. Aggrecanase-1 (1 nM) was incubated at 37°C for 30 min with bovine nasal aggrecan monomer (0.1-500 nM). Following the incubation, free aggrecanase-1 was separated from bound protein by filtration and the percentage of bound aggrecanase-1 was plotted against aggrecan concentration (Fig. 6A) . From these data, the apparent K d was estimated to be 10.6 nM.
The concentration-dependent inhibition of aggrecanase-1 binding to aggrecan by the TSP peptide 2 was next evaluated. Aggrecanase-1 was incubated for 15 min at 37°C with the peptide GGWGPWGPWGDCSRTCGGG, followed by addition of the aggrecan monomer (500 nM) and an additional 30-min incubation. Free aggrecanase-1 was separated from the bound protein by filtration, and the filtrates were analyzed for free aggrecanase-1 by ELISA. The percentage of free aggrecanase-1 was plotted against the concentration of the TSP peptide, and the IC 50 was estimated to be 5 M (Fig. 6B) . Using this value and the determined K d of aggrecan binding (10.6 nM), the apparent K i for the TSP peptide 2 was estimated to be 105 nM.
Finally, we evaluated at the ability of aggrecanase-1 to cleave GAG-free aggrecan as compared with native aggrecan. Aggrecanase-1 was incubated with native or GAG-free aggrecan at 37°C for 0 -1 h, and the reaction mixtures were analyzed for aggrecan fragments generated by cleavage between residues Glu 1667 /Gly 1668 , residues Glu 1480 /Gly 1481 , and residues Glu 373 /Ala 374 , using the anti-KEEE, anti-GELE, and BC-3 antibodies, respectively. Aggrecanase-1 cleaved native aggrecan in a time-dependent manner between residues Glu 1667 and Gly 1668 to generate KEEE-reactive fragments (Fig. 7A) , between residues Glu 1480 and Gly 1481 to generate GELE-reactive fragments (Fig. 7B) , and between residues Glu 373 and Ala 374 to generate BC-3-reactive fragments (Fig. 7C) , but did not cleave the GAG-free aggrecan at any of these sites to generate immunoreactive fragments. Evaluation of these reaction mixtures for general cleavage by Western analysis using the MAB2035 antibody showed no decrease in intensity of the band representing intact aggrecan and no appearance of smaller molecular mass bands when GAG-free aggrecan was used as the substrate (Fig.  7D) . These data confirm lack of cleavage of GAG-free aggrecan at these sites and indicate that aggrecanase-1 also did not cleave GAG-free aggrecan at any other sites within the molecule over this time period. . Bovine aggrecan (500 nM) was incubated at 37°C with 5 nM aggrecanase-1 (ADAMTS-4) in the absence (Ϫ) or presence (ϩ) of 100 M peptide, GGWGPWGPWGDCSRTCGGG, for 0.5 h for analysis of KEEE-reactive fragments (A), 1 h for analysis of GELE-reactive fragments (B), or 5 h for analysis of BC-3-reactive fragments (C).
TABLE II Thrombospondin motif peptide, GGWGPWGPWGDCSRTCGGG, blocks binding of aggrecanase-1 (ADAMTS-4) to aggrecan
Aggrecanase-1 (1 nM) was incubated with 500 nM deglycosylated aggrecan, native aggrecan or native aggrecan in the presence of 100 M TSP peptide, GGWGPWGPWGDCSRTCGGG. Following the incubation, free aggrecanase-1 was separated from bound protein using Micron 100 kDa size-exclusion filter units. The amount of aggrecanase-1 in the filtrate was monitored using an aggrecanase-1 ELISA. 
DISCUSSION
These studies clearly demonstrate that the TSP-1 motif located within the C terminus of aggrecanase-1 is important for aggrecan binding and cleavage. Furthermore, the data suggest that aggrecanase-1 binds aggrecan through interaction of its TSP-1 motif with the GAG side chains of aggrecan. Removal of the GAG from aggrecan results in the loss of aggrecanase-1 binding and cleavage, and both binding and cleavage of native aggrecan by aggrecanase-1 were blocked with peptides corresponding to regions of the TSP-1 motif. These data suggest that peptides representing specific sequences within the TSP motif may serve to inhibit aggrecanase-mediated aggrecan degradation.
The peptide GGWGPWGPWGD (peptide 1) from the aggrecanase-1 TSP-1 motif, corresponding to the sequence implicated in the interaction of thrombospondin with sulfated GAG chains, was effective in blocking cleavage of aggrecan with an IC 50 of 17 M. However, extension of the peptide to include the sequence CSRTCG representing the CD36 binding region in thrombospondin, resulted in a peptide (peptide 2) that was more potent in inhibiting aggrecan cleavage (IC 50 ϭ 3 M). These data suggest that sequences corresponding to both the GAG-binding region and CD36 binding motif of thrombospondin may play a role in aggrecanase binding to and cleavage of aggrecan. Little inhibition was seen with peptides representing other regions of the TSP-1 motif, with the exception of the C-terminal region, GGKYCEGRRTRFSCNTEDCP, which inhibited cleavage with an IC 50 of 38 M. This sequence does not contain sequences corresponding to the GAG-binding regions of thrombospondin or to the CD36 binding motif. Therefore, the specific region in this peptide responsible for binding remains to be determined.
Our demonstration that the binding of aggrecanase-1 to aggrecan is blocked by a TSP-1 peptide containing the GAGbinding region of this motif in thrombospondin suggests that binding involves the GAG of aggrecan. Additional evidence is provided by the data showing that aggrecanase-1 binds to native but not GAG-free aggrecan. Finally, the lack of cleavage of the GAG-free aggrecan substrate by aggrecanase-1 provides further support. A recent report showing inhibition of partially purified aggrecanase activity by chondroitin sulfate (36) is also consistent with this hypothesis.
Studies evaluating binding of aggrecanase-1 to aggrecan demonstrated that the IC 50 of peptide 2 (5 M) for inhibition of binding was similar to that for its inhibition of cleavage of aggrecan (3 M), consistent with the hypothesis that binding of aggrecanase-1 to the GAG chains is important for cleavage of aggrecan.
Although our experiments were not designed to directly measure TSP peptide binding to aggrecan, in many cases that K i is equivalent to K d . Based on the data generated, if we make this assumption, then the affinity of the TSP peptide to aggrecan (K i ϭ 105 nM) is 1 log less than the affinity of aggrecanase-1 for aggrecan (K d ϭ 10.6 nM). The most likely reasons for the apparent lower affinity of the peptide are as follows. 1) It is a linear peptide lacking a tertiary structure, which may be necessary for binding; or 2) there are other binding sites on aggrecanase-1, which add to the overall affinity of aggrecan binding, which the TSP peptide would not contain. The TSP peptide represents just a portion of the TSP motif. Therefore, it is possible that a peptide spanning the entire region may show a binding affinity comparable to aggrecanase-1 protein.
The ability of the TSP-1 motif of aggrecanase-1 to inhibit aggrecan cleavage suggests that C-terminal fragments of the protein may have the ability to inhibit cleavage of aggrecan. Western analysis of cartilage explant culture media for aggrecanase-1 using an antibody that recognizes the catalytic domain of the enzyme, showed several bands with a lower molecular mass than the mature protein, 5 indicating that a portion of the aggrecanase-1 protein had lost the C-terminal region representing the TSP motif. This opens the possibility that Cterminal cleavage of the aggrecanase protein may serve as a control mechanism to regulate aggrecan degradation by this enzyme. Loss of the C terminus would not only decrease the ability of the active enzyme to cleave the aggrecan substrate, but fragments containing the TSP-1 motif might also serve to inhibit aggrecan cleavage by the remaining full-length enzyme by competing with its binding to the GAG of aggrecan.
The peptide GGWGPWGPWGDCSRTCGGG, containing both the putative GAG-binding sequence and CD36 binding sequence, was effective in blocking aggrecanase-1 activity. Therefore, theoretically any protein containing these sequences could potentially act as an endogenous inhibitor of aggre-5 M. D. Tortorella and E. C. Arner, unpublished data.
FIG. 6.
Binding of aggrecanase-1 (ADAMTS-4) to aggrecan. A, aggrecanase-1 (1 nM) was incubated at 37°C for 30 min with bovine nasal aggrecan monomer (0.1-500 nM). Following the incubation, free aggrecanase-1 was separated from bound protein by filtration and the concentration of free aggrecanase-1 in the filtrate was determined by ELISA. The percentage of bound aggrecanase-1 was plotted against aggrecan concentration. B, aggrecanase-1 (1 nM) was incubated for 15 min at 37°C with the peptide GGWGPWGPWGDCSRTCGGG (0.1-100 M), followed by addition of the aggrecan monomer (500 nM) and an additional 30-min incubation. Free aggrecanase-1 was separated from the bound protein by filtration, and the filtrate was analyzed for free aggrecanase-1 by ELISA. The percentage of free aggrecanase-1 was plotted against the concentration of the TSP peptide.
canase. Human proteins found to have homologous sequences include thrombospondin-1, thrombospondin-2, ADAMTS-1, ADAMTS-4 (aggrecanase-1), ADAMTS-5/11 (aggrecanase-2), ADAMTS-8, sco-spondin-mucin-like protein, properdin, and brain-specific angiogenesis inhibitor 2. Of these proteins, AD-AMTS-1, ADAMTS-4, ADAMTS-5/11, and thrombospondins-1 and -2 (1, 2, 37, 38) have been demonstrated to be present in the cartilage extracellular matrix. ADAMTS-4 and -5/11 represent aggrecanase-1 and -2, respectively, and have both been shown to efficiently cleave cartilage aggrecan. In contrast, we have found that ADAMTS-1 is ineffective in cleaving aggrecan (data not shown). Therefore, since it contains a homologous peptide sequence, it may be capable of acting as an inhibitor of aggrecanase-1 and -2 by competing for binding sites on the aggrecan molecule. Thrombospondin-1 and -2 each contain three repeating TSP motifs with homologous sequences. Therefore, these thrombospondins, or thrombospondin fragments that contain any of the TSP type-1 motifs, may serve as endogenous inhibitors of aggrecanase. We have found relatively high levels of thrombospondin-1 in the cartilage extracellular matrix (approximately 0.1-1 M), and thrombospondin-1 fragments in media from cartilage explants stimulated with cytokines. More importantly we have demonstrated that thrombospondin-1 blocks both aggrecanase-1 and -2 cleavage of aggrecan with an IC 50 of approximately 300 nM (data not shown). Thus, it is interesting to speculate that thrombospondins may represent endogenous inhibitors of aggrecanase-1 and -2. We are currently exploring what role the thrombospondins may play in the regulation of aggrecanase-mediated aggrecan breakdown in models of cartilage degradation.
The ability of thrombospondin-1 to suppress angiogenesis has been identified with two independent regions within the TSP type-1 motifs of the molecule: the tryptophan-rich W(S/ G)XW motifs and the CD36 binding region. In addition, METH-1 and -2 (ADAMTS-1 and ADAMTS-8) have recently been shown to inhibit angiogenesis through their TSP-1 motifs (6). Since similar sequences are present in the TSP-1 motif of both aggrecanase-1 and -2, the C terminus of these enzymes may also have the capacity to inhibit angiogenesis. Articular cartilage is an avascular tissue, although the mechanism responsible for this property is still unclear. Therefore, it is interesting to speculate that the aggrecanases may have an additional function in contributing to the suppression of vasularization of the cartilage matrix.
The studies reported herein demonstrate an important role for the C terminus of aggrecanase-1 in the ability of this enzyme to bind to and cleave the aggrecan substrate. In addition, they suggest that this property is mediated through binding of particular regions of the TSP type-1 motif to the GAG side chains of aggrecan. Therefore, our data raise the possibility -1 (ADAMTS-4) . Native aggrecan or deglycosylated aggrecan at a concentration of 500 nM was incubated with 5 pM aggrecanase-1 for 0, 0.25, 0.5, and 1 h at 37°C. Following incubation the reaction mixture was analyzed for cleavage of aggrecan between residues Glu 1667 and Gly 1668 using the KEEE antibody (A), between residues Glu 1480 and Gly 1481 using the GELE antibody (B), between residues Glu 373 and Ala 374 using the BC-3 antibody (C), and for general cleavage using the MAB2035 antibody (D).
